Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2

PLoS One. 2023 Jul 28;18(7):e0289024. doi: 10.1371/journal.pone.0289024. eCollection 2023.

Abstract

Background: Cancer relapse is associated with the presence of cancer stem-like cells (CSCs), which lead to multidirectional differentiation and unrestricted proliferative replication. Fumagillin, a myocotoxin produced by the saprophytic filamentous fungus Aspergillus fumigatus, has been reported to affect malignant characteristics in hepatocellular cancer cells. However, its exact role in CSCs is still unknown.

Methods: CSCs were enriched by culturing cancer cells in serum-free medium. The effects of fumagillin on malignant cell characteristics and mitochondrial function were measured. The regulatory role of fumagillin on methionine aminopeptidase-2 (MetAP-2) was assessed.

Results: When it was supplemented in medium, fumagillin treatment inhibited sphere formation and the maintenance of stemness of CSCs without disturbing cell growth. Fumagillin also decreased stemness-related markers and the aldehyde dehydrogenase 1 (ALDH1)-positive proportion, which demonstrated that fumagillin decreases stemness in CSCs. It was also found to inhibit malignant traits in CSCs, including cell proliferation, invasion, and tumor formation, and sensitize CSCs to chemoagents, including sorafenib and doxorubicin, by promoting chemoagent-induced apoptosis. Moreover, fumagillin treatment was found to disturb mitochondrial membrane homeostasis, ATP synthesis and mitochondrial transcriptional activity. In addition, we found that fumagillin decreased MetAP-2 protein levels and exerted anti-CSC effects potentially by regulating MetAP-2. We also found that fumagillin treatment activated p53 and its transcriptional activity and thus caused cell cycle blockade. Moreover, fumagillin treatment significantly decreased tumor formation in nude mice.

Conclusion: This work offers evidence for fumagillin as a specific inhibitor of liver cancer CSCs and proposes a novel strategy for cancer therapy.

Publication types

  • Retracted Publication

MeSH terms

  • Aminopeptidases / metabolism
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Liver Neoplasms* / pathology
  • Mice
  • Mice, Nude
  • Neoplasm Recurrence, Local* / pathology
  • Neoplastic Stem Cells / metabolism

Substances

  • methionine aminopeptidase 2
  • fumagillin
  • Aminopeptidases

Grants and funding

This work was supported by The General Program (Key Program, Major Research Plan) of National Natural Science Foundation of China (No. 82074298). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.